PRTC News and Press, PureTech Health plc From 06/06/22

Franklin brings proven track record leading early commercialization and growing disruptive healthcare business models, including at Exact Sciences, Foundation Medicine and Boston Scientific Franklin to oversee Akili’s Commercial, Product, Engineering, Medical and Pe...

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced that Bharatt Chowrira, Ph.D., J.D....

The Roblox vision for bringing people together through shared experiences, plus the Akili commitment to a new era of cognitive medicine, make the companies ideal partners to deliver a reimagined patient experience PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (ȁ...

Data presentations include review of the VE303 Phase 2 CONSORTIUM study, in which VE303 was well tolerated and highly active at preventing Clostridioides difficile infection recurrence in subjects at high risk of recurrence Further CONSORTIUM study analysis shows that the ...

Data presentations include review of the VE303 Phase 2 CONSORTIUM study, in which VE303 was well tolerated and highly active at preventing Clostridioides difficile infection recurrence in subjects at high risk of recurrence Further CONSORTIUM study analysis shows that the ...

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced that George Farmer, Ph.D., Chief F...

Further data from Phase 1 study in healthy older adults demonstrate improved tolerability profile of LYT-100 compared to pirfenidone Data support the planned LYT-100 dose-ranging registration-enabling studies in idiopathic pulmonary fibrosis, with topline results expected in 2...

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, announces that, in connection with the $50 million...

PureTech Health (NASDAQ:PRTC) board approved a share buyback program in respect of its ordinary shares of one pence each up to a maximum consideration of $50M. The company consolidated cash and cash equivalents of $465.7M and $413.2M at Dec. 31, 2021 and Mar. 31, 2022, respectively. The ...

Previous cash runway guidance into the first quarter of 2025 remains in place PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentia...